Clinical Trial Update: A Study of Cabozantinib Compared With Placebo in Subjects With Radioiodine-refractory Differentiated Thyroid Cancer Who Have Progressed After Prior Vascular Endothelial Growth Factor Receptor (VEGFR) -Targeted Therapy [Phase 3]

View source ↗

Summary

Phase 3 study comparing cabozantinib to placebo in radioiodine-refractory differentiated thyroid cancer after prior VEGFR-targeted therapy; results were posted …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Differentiated Thyroid Cancer

Drugs mentioned

• cabozantinib (cabozantinib)

Snippet

Sponsor: Exelixis | Conditions: Differentiated Thyroid Cancer | Phase 3 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2023-05-18